Navigation Links
ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
Date:2/7/2008

SAN DIEGO, Feb. 7 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), announced today that complete pharmacokinetic data from the Company's marketing-enabling bioequivalence clinical study of ANX-530 (vinorelbine emulsion) has been accepted for presentation at the 2008 American Association for Cancer Research (AACR) Annual Meeting, which takes place April 12 - 16, 2008 in San Diego, CA.

The poster presentation entitled "Pharmacokinetic equivalence observed between an emulsion formulation of vinorelbine (ANX-530) and vinorelbine solution in a clinical study of patients with advanced cancer," is scheduled to be presented on April 13, 2008.

ADVENTRX recently completed a marketing-enabling bioequivalence clinical study of ANX-530. The primary endpoint in the study was met, with pharmacokinetic equivalence observed between ANX-530 and the reference drug Navelbine(R). Furthermore, ANX-530 demonstrated a statistically significant reduction in injection site reactions when compared to Navelbine. Presentation of complete safety results including injection site reactions, have been submitted for presentation at an upcoming oncology conference. ADVENTRX intends to submit to the U.S. Food and Drug Administration (FDA) a Section 505(b)(2) New Drug Application (NDA) for ANX-530 in the fourth quarter of 2008.

About ANX-530 (vinorelbine emulsion)

ANX-530 is designed to reduce the incidence and severity of injection site reactions from intravenous delivery of vinorelbine tartrate. Vinorelbine tartrate works by disrupting microtubule formation and is a member of the vinca alkaloid class of antineoplastic agents. Vinorelbine is indicated as a single agent or in combination with cisplatin for treatment of advanced
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ADVENTRX Announces Consolidation of Clinical and Management Positions
2. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
3. ADVENTRX Appoints Vice President of Commercialization
4. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
5. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
6. ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
7. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference
8. ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
9. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
10. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 While administrative claims and ... research for a relatively long period of time, ... the use of these ‘big data’ for comparisons ... combining today’s powerful computer technology with the plethora ... data’ holds significant promise for identifying optimal interventions ...
(Date:7/30/2014)... , July 30, 2014   Wyle ... the Fully Integrated Lifecycle Mission Support Services (FILMSS) ... Administration (NASA). Under the terms of the contract, ... Center at Moffett Field, Calif. In particular, Wyle ... bioscience flight development projects on the International Space ...
(Date:7/30/2014)... July 30, 2014 BCC Research ( ... Markets for Enzymes in Industrial Applications , the global ... nearly $7.1 billion by 2018, registering a five-year compound ... estimated to be recorded in the detergent enzyme segment ... , Enzyme technology has influenced almost every sector of ...
(Date:7/30/2014)... , July 30, 2014  Orexigen Therapeutics, Inc. ... received the Day 180 List of Outstanding Issues (LOI) ... for Human Use (CHMP) for the NB32 Marketing Authorization ... SR) is an investigational drug candidate being evaluated for ... earlier Day 120 time point were adequately addressed by ...
Breaking Biology Technology:Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3
... 2011 Arecor, the leading company ... and vaccines, is pleased to announce the appointment ... Howell will be responsible for the operations of ... Arecor,s upward growth curve ensuring the company continues ...
... Nov. 10, 2011 Avaxia Biologics, Inc. , ... act locally within the gastrointestinal tract, announced today that ... of a Series A angel-led financing. Cherrystone Angels of ... Boston Harbor Angels and other undisclosed individuals. Mr. Robert ...
... Discovery Laboratories, Inc. (Nasdaq: DSCO ), ... respiratory critical care, today reports financial results for the third ... of the SURFAXIN® and AFECTAIR™ programs.  The Company will host ... call details are below. Selected third quarter highlights ...
Cached Biology Technology:Arecor Appoints Dr. Sarah Howell as Chief Operating Officer 2Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease 2Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 2Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 3Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 4Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 5Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 6Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 7Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 8Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs 9
(Date:7/30/2014)... biologists, led by Clemson University associate professor Andrew S. ... will pave the way for novel anti-fouling paint for ... and industrial applications. , The team,s findings, published in ... larval stage of barnacles that attaches to a wide ... material that acts as an underwater heavy-duty adhesive. , ...
(Date:7/30/2014)... , July 30, 2014 NexID ... and liveness detection solutions for the biometric authentication ... industry consortium revolutionizing online authentication with standards for ... Cornett , "The decision to join FIDO Alliance ... authentication pervasive in use. We believe the FIDO ...
(Date:7/30/2014)... out how to create colors, nature had already perfected ... many different hues, for example. Now scientists are tapping ... way to make colored plastics. Their paper on using ... rather than dyes, to produce color appears in ... Asger Mortensen, Anders Kristensen and colleagues point out that ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2NexID Biometrics Joins the FIDO Alliance 2
... Va. A five-year-old Virginia Tech outreach program, ... doing research and providing results that scientists can ... Partnership Award from the National Center for Research ... of Health. The Fralin Life Science Institute,s Partnership ...
... If you would like to receive Science Picks via e-mail, ... to receive it, please e-mail kcapelli@usgs.gov . October ... Sumatra Earthquakes, DOI Prepared to Address Climate Change, Water is ... of Seismic Proportions, Forget the Garlic Necklace! Learn More about ...
... attention to National Child Health Day (today), the Preventive Cardiovascular ... consumer survey and launched a campaign to educate families about ... The national survey revealed that more than three in ... heart disease do not begin until adulthood. ...
Cached Biology News:NIH funds new phase of high school-university research partnership 2NIH funds new phase of high school-university research partnership 3USGS Science Picks 2USGS Science Picks 3USGS Science Picks 4USGS Science Picks 5USGS Science Picks 6USGS Science Picks 7USGS Science Picks 8USGS Science Picks 9Americans concerned about heart health, but not proactive enough to prevent it 2
...
BD BioCoat Poly-D-Lysine 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine....
... 4000 incorporates the critical design features demanded ... biomarker research. The Series 4000 delivers improved ... biomarker discoveries to biomarker assays all on ... designed to fit into the research plans ...
Gelatin 100 mm Culture Dishes...
Biology Products: